Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
37
RXRX Quote, Financials, Valuation and Earnings
Last price:
$7.09
Seasonality move
:
-18.3%
Day range:
$6.10 - $7.01
52-week range:
$5.60 - $15.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
26.59x
P/B ratio:
3.82x
Volume:
20.6M
Avg. volume:
14.9M
1-year change:
-32.27%
Market cap:
$2B
Revenue:
$43.9M
EPS (TTM):
-$1.55
Analysts' Opinion
-
Consensus RatingRecursion Pharmaceuticals has received a consensus rating of . The company's average rating is a based on 1 Buy rating, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Recursion Pharmaceuticals has an estimated upside of 41.02% from its current price of $6.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $6.99.
Fair Value
-
According to the consensus of 0 analysts, Recursion Pharmaceuticals has 41.02% upside to fair value with a price target of -- per share.
RXRX vs. S&P 500
-
Over the past 5 trading days, Recursion Pharmaceuticals has underperformed the S&P 500 by -7.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Recursion Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Recursion Pharmaceuticals has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Recursion Pharmaceuticals reported revenues of $26.1M.
Earnings Growth
-
Recursion Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Recursion Pharmaceuticals reported earnings per share of -$0.34.
Enterprise value:
1.6B
EV / Invested capital:
2.90x
Price / LTM sales:
26.59x
EV / EBIT:
--
EV / Revenue:
24.84x
PEG ratio (5yr expected):
-0.73x
EV / Free cash flow:
-4.78x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$22.3M
Return On Assets:
-56.47%
Net Income Margin (TTM):
-584.75%
Return On Equity:
-78.32%
Return On Invested Capital:
-76.3%
Operating Margin:
-377.1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $28.5M | $46.9M | $64.6M | $10.1M | $26.1M | |
| Gross Profit | -$8.9M | $3.4M | $22.3M | -$775K | $14M | |
| Operating Income | -$249.7M | -$312.1M | -$394.2M | -$99.6M | -$98.4M | |
| EBITDA | -$236.1M | -$272.4M | -$350.9M | -$85.4M | -$87.9M | |
| Diluted EPS | -$1.44 | -$1.46 | -$1.55 | -$0.43 | -$0.34 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $600.9M | $481.6M | $410.5M | $474.2M | |
| Total Assets | -- | $658.6M | $611.5M | $630.8M | $726.5M | |
| Current Liabilities | -- | $42.9M | $83M | $94.1M | $108.9M | |
| Total Liabilities | -- | $59.6M | $223.5M | $192.9M | $201.9M | |
| Total Equity | -- | $599M | $388M | $438M | $524.6M | |
| Total Debt | -- | $744K | $656K | $1.8M | $28.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$99.9M | -$258.5M | -$317.8M | -$72.9M | -$59.2M | |
| Cash From Investing | $149M | -$15.7M | -$17.9M | -$347K | -$4.6M | |
| Cash From Financing | $10.9M | $206.7M | $374.1M | $53.8M | $16.5M | |
| Free Cash Flow | -$133.8M | -$276.6M | -$335.6M | -$73.7M | -$63.8M | |
RXRX
Sector
Market Cap
$2B
$45.6M
Price % of 52-Week High
44.41%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
-19.79%
-0.74%
1-Year Price Total Return
-32.27%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$6.73
200-day SMA
Sell
Level
$7.78
Bollinger Bands (100)
Buy
Level
6.19 - 7.27
Chaikin Money Flow
Sell
Level
-109.9M
20-day SMA
Buy
Level
$6.94
Relative Strength Index (RSI14)
Buy
Level
51.49
ADX Line
Buy
Level
18.34
Williams %R
Neutral
Level
-70.7182
50-day SMA
Buy
Level
$6.77
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
96.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.2219)
Sell
CA Score
(Annual)
Level (-1.729)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (2.8144)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Stock Forecast FAQ
In the current month, RXRX has received 1 Buy ratings 6 Hold ratings, and 0 Sell ratings. The RXRX average analyst price target in the past 3 months is --.
-
Where Will Recursion Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Recursion Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Recursion Pharmaceuticals?
Analysts are divided on their view about Recursion Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Recursion Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Recursion Pharmaceuticals's Price Target?
The price target for Recursion Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is RXRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Recursion Pharmaceuticals is a . 0 of 0 analysts rate the stock a at this time.
-
How Can I Buy Shares Of RXRX?
You can purchase shares of Recursion Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Recursion Pharmaceuticals shares.
-
What Is The Recursion Pharmaceuticals Share Price Today?
Recursion Pharmaceuticals was last trading at $7.09 per share. This represents the most recent stock quote for Recursion Pharmaceuticals. Yesterday, Recursion Pharmaceuticals closed at $6.99 per share.
-
How To Buy Recursion Pharmaceuticals Stock Online?
In order to purchase Recursion Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.34% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.68% over the past day.
